Specifically, a study has shown that SHP2 inhibition, using the SHP2 inhibitor SHP099, could efficiently reduce RAS-GTP loading, block RAS-mediated RAF/MEK/ERK signaling and abrogate tumor growth in NF1-malignant peripheral nerve sheath tumors (MPNSTs) (Table 1) [110]. Here, PTPN11 is linked to malignant peripheral nerve sheath tumor.